M Proskurin

Pharmacoeconomic Analysis of the use of Everolimus Compared to Axitinib in Second Line Therapy of Patients with Metastatic Renal Cell Carcinoma.

diversity of the health professionals and the basic scenario. The costliest scenarios were the one implementing HPV DNA testing which did not provide further participation despite a high cost and the one based on P4P incentives towards GP, although it allows high participation rates. ConClusions: Using a comprehensive BIM, we show that full coverage of OS might be the most cost-effective way to implement it, although practical and financial issues might favour other scenarios that may be more balanced regarding the distribution of costs between stakeholders or may be more easily implemented and accepted by health professionals.

Budget Impact Analysis of the Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors – Nilotinib in the First and Second Lines of Therapy

chemotherapy after the index date to the earliest of mean time to HSCT, death, loss to follow-up, or last chemotherapy dose plus 30 days. The primary endpoint was the percent of time in the hospital during the salvage chemotherapy period. Key secondary endpoints were number of hospitalisations and length of hospital stay. Hospitalisations associated with HSCT were excluded. Results are presented as mean (SD) unless indicated. Results: Twenty-two patients were included, with a mean age of 44 (18) years. After the index date, 19 patients died and 8 patients received a HSCT. During the chemotherapy salvage period, patients spent a mean of 56% (95% CI: 46%-69%) of their time in the hospital. There were a mean of 2.2 (1.5) inpatient hospitalisations, 3.2 (6.2) day stays, and 1.6 (3.0) outpatient visits per patient, and the mean length of inpatient hospitalisation was 20.0 (20.0) days. From the index date to death, there were a mean of 2.8 (1.4) inpatient hospitalisations, 4.7 (7.3) day stays, and 4.6 (7.4) outpatient visits per patient and the mean length of inpatient hospitalisation was 19.0 (19.0) days. ConClusions: Adult patients receiving salvage chemotherapy for R/R ALL in Italy spend more than half their time in the hospital. Costs of hospitalisations will be presented.